<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141632</url>
  </required_header>
  <id_info>
    <org_study_id>GATE</org_study_id>
    <nct_id>NCT03141632</nct_id>
  </id_info>
  <brief_title>Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake</brief_title>
  <acronym>GATE</acronym>
  <official_title>Effects of GLP-1 Analogues on Fluid Intake in Healthy Volunteers - &quot;The GATE-Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to elucidate whether GLP-1 analogues influence not only appetite but
      also thirst perception. It is hypothesized that GLP-1 analogues reduce fluid intake in
      healthy volunteers compared to Placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GLP-1 analogues are well known to stimulate glucose-induced insulin secretion and to reduce
      energy intake. Recent findings from animal and human studies suggest a role of GLP-1 in
      regulating water and salt homeostasis. GLP-1 has been shown to reduce fluid intake after an
      oral salt load or during a meal - pointing to a hypodipsic effect. The aim of this study is
      to elucidate whether these putative hypodipsic properties of GLP-1 analogues reduce fluid
      intake in healthy volunteers compared to placebo assessed during an evaluation visit of 8
      hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2016</start_date>
  <completion_date type="Actual">May 12, 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo control, cross-over design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fluid intake</measure>
    <time_frame>8 hours</time_frame>
    <description>Fluid intake (ml) during an evaluation visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thirst</measure>
    <time_frame>8 hours</time_frame>
    <description>Thirst perception</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine volume</measure>
    <time_frame>24 hours</time_frame>
    <description>Urine volume in ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary sodium</measure>
    <time_frame>24 hours</time_frame>
    <description>Urinary sodium excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolytes</measure>
    <time_frame>3 timpoints during 8 hours</time_frame>
    <description>Plasma electrolytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine electrolytes</measure>
    <time_frame>3 timpoints during 8 hours</time_frame>
    <description>Urine electrolytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>copeptin</measure>
    <time_frame>3 timpoints during 8 hours</time_frame>
    <description>copeptin values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renin</measure>
    <time_frame>3 timpoints during 8 hours</time_frame>
    <description>renin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aldosterone</measure>
    <time_frame>3 timpoints during 8 hours</time_frame>
    <description>aldosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Water and Salt</measure>
    <time_frame>3 timpoints during 8 hours</time_frame>
    <description>Brain Natriuretic Peptide (BNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1</measure>
    <time_frame>3 timpoints during 8 hours</time_frame>
    <description>GLP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamus Pituitary Adrenal Axis (HPA)</measure>
    <time_frame>8 hours after Dexamethasone intake</time_frame>
    <description>cortisol value after Dexamethasone intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circadian rhythm</measure>
    <time_frame>16 hours</time_frame>
    <description>circadian rhythm of serum cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>salivary cortisol</measure>
    <time_frame>16 hours</time_frame>
    <description>circadian rhythm of salivary cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACTH</measure>
    <time_frame>16 hours</time_frame>
    <description>circadian rhythm of ACTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamus Pituitary Adrenal Axis (HPA)</measure>
    <time_frame>0.5 hours</time_frame>
    <description>cortisol upon adrenocorticotropic hormone (ACTH) stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamus Pituitary Adrenal Axis (HPA)</measure>
    <time_frame>24 hours</time_frame>
    <description>free urinary cortisol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Thirst</condition>
  <condition>Water-Electrolyte Imbalance</condition>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dulaglutide (TrulicityÂ®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Evaluation visit with assessment of fluid intake</description>
    <arm_group_label>Dulaglutide</arm_group_label>
    <other_name>Verum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Evaluation visit with assessment of fluid intake</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Age 18 to 65 years

        Exclusion Criteria:

          -  Known or probable central or nephrogenic Diabetes insipidus, based on patient's
             history

          -  Polyuria secondary to diabetes mellitus, hypokalemia, hypercalcemia

          -  Primary Polydipsia, defined as more than 4 liters fluid intake per day

          -  BMI &lt;18 or &gt;30kg/m2

          -  Pregnancy

          -  Previous treatment with GLP-1 agonists within the last 3 month

          -  History of pancreatitis

          -  Severe renal insufficiency (eGFR (CKD EPI) &lt;30 ml/min/1,73 m2)

          -  Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirjam Christ-Crain, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital fo Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Water-Electrolyte Imbalance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Dulaglutide</mesh_term>
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

